GenSight Biologics S A : Corporate presentation, January 2022

Corporate Presentation

January 2022

A LEADING Gene Therapy BIOTECHNOLOGY COMPANY

GENSIGHT-BIOLOGICS.COM

Disclaimer

This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company"), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. They include all matters that are not historical facts. These forward-looking statements can be identified by the use of forward-looking terminology including the terms "developments," "estimates," "expects," "intends," "may," "milestones," "potential," "value," "time to market," "targeting," "on track," "planned," "will," "move to," or other variations or comparable terminology, or by discussions of strategy and funding, as well as the Company's, its subsidiaries' and affiliates' technology, and are based on financial and non-financial information, including projections as to the future regulatory situation and other information and assumptions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may

depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of the Company, its subsidiaries and affiliates or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company, its subsidiaries and affiliates disclaim any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any events, or changes in conditions or circumstances on which any such statement, forecast or estimate is based.

2 January 2022 - non confidential

Investment Case - Transitioning from R&D to Commercial Organization

1

2

3

4

5

Late-stage Biotech

company

Seasoned

management team /

Potential NASDAQ

Listing

LUMEVOQ®

Strong clinical data in

LHON

H1 2023 LUMEVOQ®

European launch

Cutting hedge optogenetics in Retinitis Pigmentosa

Public company founded in 2012 dedicated to developing and commercializing gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

Euronext Listed SIGHT / €265m Market Cap / Avg. 30-day Daily volume: 0.5% of O/S

Management team with strong and highly relevant Biotech experience in R&D and commercialization

Solid investor base of Healthcare specialist investors, including US based investors. Contemplating potential secondary NASDAQ listing

LUMEVOQ® completed 3 Phase III studies in Leber Hereditary Optic Neuropathy (ND4 LHON), a rare and highly debilitating genetic ophthalmic disease leading to sudden loss of central vision and affecting c. 1,200 - 1,500 new patients / year in Europe and the US

Dedicated team in place to accelerate/optimize LUMEVOQ® access in key European territories Available in France through ATU at €700,000 for a bilateral injection

EU regulatory review ongoing - on track for potential approval in Q4 2022 and launch in Q1 2023 Ongoing discussion with US FDA to confirm regulatory timeline

GS030 outstanding early findings reporting blind patients to precisely identify objects (published in Nature Medicine in May 21)

Extension cohort currently being recruited

3 January 2022 - non confidential

Seasoned Executive Team

Bernard Gilly

Chief Executive Officer

PIXIUM VISION (Since 2011) FOVEA PHARMA (2005-2009) SOFINNOVA PARTNERS (2000-2005) TRANSGENE (1992-2000)

Ph.D. in biology and bio-economics

Thomas Gidoin

Chief Financial Officer

DBV TECHNOLOGIES (2012-2015) IPSEN (2008-2011)

ERNST & YOUNG (2007-2008)

Magali Taiel

Chief Medical Officer

ProQR THERAPEUTICS (2016-2018)

ELI LILLY (2004-2016)

PFIZER (2001-2004)

SERVIER (1999-2001)

M.D., Board-certified ophthalmologist

Catherine Cancian

VP of Pharmaceutical Operations

GENETHON (2015-2017)

SANOFI PASTEUR (1998-2014)

4 January 2022 - non confidential

Julio Benedicto

VP of Marketing

IMS CONSULTING (2011-2017) BOOZ & COMPANY (2010-2011) MONITOR GROUP (1994-2009)

Marie-Claude Holtz

VP of Quality

EXELTIS SANTE (2016-2019)

PFIZER (2015-2016)

ABBVIE (2014-2015)

GALDERMA (2012-2013)

LABORATOIRE LAFON (TEVA) (1993-2012)

Pharm.D.

Leigh Shaw

VP of Regulatory Affairs

UNITED NEUROSCIENCE (2017-2020) NIGHTSTARX (2015-2017)

GREGORY FRYER ASSOCIATES (2005-2015) HUNTINGDON LIFE SCIENCES (2002-2005) CANTAB PHARMACEUTICALS (1995-2001)

Pipeline: solid and advanced product portfolio in ophthalmic Gene Therapy

MTS Platform

LHON ND4 (EU)

EMA Orphan Drug Designation

LHON ND4 (US)

FDA Orphan Drug Designation

GS011 LHON ND1

New Undisclosed

Optogenetics

GS030	Retinitis Pigmentosa (RP)
EMA & FDA Orphan Drug Designation

GS030	Dry AMD &
Geographic Atrophy

				Expected
Preclinical	Phase I / II	Phase III	Registration	Approval	Market Opportunity
				End 2022	~ 400 new patients per year
					~ 600 new patients per year
					~ 100 new patients per year
					~ 1,500 new patients per year

	2024	~ 15-20,000 new patients per year
2024		~ 350-400,000 new patients per year

5 January 2022 - non confidential